Research progress on natural bioactive components in the treatment of pulmonary arterial hypertension

doi:10.16352/j.issn.1001-6325.2026.08.1130

Abstract

Abstract: Pulmonary arterial hypertension(PAH) is characterized by pulmonary vascular remodeling, which is difficult to reverse with current therapies. Natural bioactive components provide a novel strategy for PAH intervention due to their multi-target advantages. This review systematically summarizes the mechanistic characteristics of natural bioactive components against PAH, encompassing multi-dimensional network effects such as improving vasomotor function, inhibiting smooth muscle cell proliferation, modulating inflammatory responses, and correcting metabolic reprogramming. Furthermore, it profoundly analyzes the evidence limitations in current research regarding direct molecular target validation, experimental models, structural endpoint evaluation, and druggability. Finally, we provide translational perspectives on strengthening target validation, upgrading pre-clinical evaluation systems, and optimizing delivery systems, aiming to provide a reference for promoting the substantive clinical translation of natural bioactive components in PAH.

Key words: pulmonary arterial hypertension, natural bioactive components, translational medicine

CLC Number:

R285.5
R543

YANG Chunyan, ZHANG Jiawei, XING Yanjiang, LI Bin, LIU Haitao. Research progress on natural bioactive components in the treatment of pulmonary arterial hypertension[J]. Basic & Clinical Medicine, 2026, 46(8): 1130-1134.

References

[1] Humbert M, Kovacs G, Hoeper MM, et al. 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension[J]. Eur Respir J, 2023, 61: 2200879. doi:10.1183/13993003.00879-2022.
[2] Mocumbi A, Humbert M, Saxena A, et al. Pulmonary hypertension[J]. Nat Rev Dis Primers, 2024, 10: 1. doi:10.1038/s41572-023-00486-7.
[3] Maron BA. Sotatercept and the clinical transformation of pulmonary arterial hypertension[J]. N Engl J Med, 2025, 392: 2059-2061.
[4] Yang X, Yang Y, Liu K, et al. Traditional Chinese medicine monomers: Targeting pulmonary artery smooth muscle cells proliferation to treat pulmonary hypertension[J]. Heliyon, 2023, 9: e14916. doi:10.1016/j.heliyon.2023.e14916.
[5] Wang X, Deng T, Zhu H, et al. Chinese herbal medicine in hypoxic pulmonary hypertension treatment: mechanisms, progress, and future directions[J]. Drug Des Devel Ther, 2025, 19: 8265-8294.
[6] Cuthbertson I, Morrell NW, Caruso P. BMPR2 mutation and metabolic reprogramming in pulmonary arterial hypertension[J]. Circ Res, 2023, 132: 109-126.
[7] Zhang JR, Ouyang X, Hou C, et al. Natural ingredients from Chinese materia medica for pulmonary hypertension[J]. Chin J Nat Med, 2021, 19: 801-814.
[8] Sun ZY, Lu GQ, Sun HY, et al. Salidroside amelio-rates hypoxic pulmonary hypertension by regulating the two-pore domain potassium TASK-1 channel[J]. Phytomedicine, 2024, 135: 156206. doi:10.1016/j.phymed.2024.156206.
[9] Li J, Zhang Z, Zhu C, et al. Salidroside enhances NO bioavailability and modulates arginine metabolism to alleviate pulmonary arterial hypertension[J]. Eur J Med Res, 2024, 29: 423. doi:10.1186/s40001-024-02016-x.
[10] Provencher S, Archer SL, Ramirez FD, et al. Standards and methodological rigor in pulmonary arterial hypertension preclinical and translational research[J]. Circ Res, 2018, 122: 1021-1032.
[11] Niu Z, Fu M, Li Y, et al. Osthole alleviates pulmonary vascular remodeling by modulating microRNA-22-3p mediated lipid metabolic reprogramming[J]. Phytomedicine, 2022, 96: 153840. doi:10.1016/j.phymed.2021.153840.
[12] Tang BL, Liu Y, Zhang JL, et al. Ginsenoside Rg1 ameliorates hypoxia-induced pulmonary arterial hypertension by inhibiting endothelial-to-mesenchymal transition and inflammation by regulating CCN1[J]. Biomed Pharmacother, 2023, 164: 114920. doi:10.1016/j.biopha.2023.114920.
[13] Li M, Ying M, Gu S, et al. Matrine alleviates hypoxia-induced inflammation and pulmonary vascular remodelling via RPS5/NF-κB signalling pathway[J]. J Biochem Mol Toxicol, 2024, 38: e23583. doi:10.1002/jbt.23583.
[14] Lei W, Chen MH, Huang ZF, et al. Salidroside protects pulmonary artery endothelial cells against hypoxia-induced apoptosis via the AhR/NF-κB and Nrf2/HO-1 pathways[J]. Phytomedicine, 2024, 128: 155376. doi:10.1016/j.phymed.2024.155376.
[15] Li W, Chen W, Peng H, et al. Shikonin improves pulmonary vascular remodeling in monocrotaline-induced pulmonary arterial hypertension via regulation of PKM2[J]. Mol Med Rep, 2023, 27: 60. doi:10.3892/mmr.2023.12947.
[16] Xi J, Ma Y, Liu D, et al. Astragaloside Ⅳ restrains pyroptosis and fibrotic development of pulmonary artery smooth muscle cells to ameliorate pulmonary artery hypertension through the PHD2/HIF1α signaling pathway[J]. BMC Pulm Med, 2023, 23: 386. doi:10.1186/s12890-023-02660-9.
[17] Tabana Y, Babu D, Fahlman R, et al. Target identifica-tion of small molecules: an overview of the current applications in drug discovery[J]. BMC Biotechnol, 2023, 23: 44. doi:10.1186/s12896-023-00815-4.
[18] Boucherat O, Agrawal V, Lawrie A, et al. The latest in animal models of pulmonary hypertension and right ventricular failure[J]. Circ Res, 2022, 130: 1466-1486.
[19] Lemay SE, Montesinos MS, Grobs Y, et al. Exploring integrin α5β1 as a potential therapeutic target for pulmonary arterial hypertension: insights from comprehensive multicenter preclinical studies[J]. Circulation, 2025, 151: 1162-1183.
[20] Asano T. Investigating the pharmacokinetics of natural products: Challenges and advances in bioavailability[J]. J Pharmacogn Nat Prod, 2024, 10: 326.
[21] Yang DP, Dong WP, Yang YC, et al. Tetramethylpyra-zine improves monocrotaline-induced pulmonary hypertension through the ROS/iNOS/PKG-1 axis[J]. J Healthc Eng, 2022, 2022: 1890892. doi:10.1155/2022/1890892.
[22] Chen Y, Lu W, Yang K, et al. Tetramethylpyrazine: A promising drug for the treatment of pulmonary hypertension[J]. Br J Pharmacol, 2020, 177: 2743-2764.
[23] Balkrishna A, Sharma N, Srivastava D, et al. Exploring the safety, efficacy, and bioactivity of herbal medicines: bridging traditional wisdom and modern science in healthcare[J]. Future Integr Med, 2024, 3: 35-49.
[24] Jyothi MV, Vl AB, Wagh VD, et al. Herbal interactions with cardiac medications: a comprehensive review of potential interactions between herbal drugs and commonly prescribed cardiac medications[J]. Curr Drug Saf, 2025, 20: 94-119.
[25] Park JS, Choi YH, Min JY, et al. Fundamental and targeted approaches in pulmonary arterial hypertension treatment[J]. Pharmaceutics, 2025, 17: 224. doi:10.3390/pharmaceutics17020224.